Clinical Trial Update: Psoriatic Immune Response to Tildrakizumab [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating the psoriatic immune response to tildrakizumab in psoriasis vulgaris.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Drugs mentioned

• Tildrakizumab (tildrakizumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Psoriasis Vulgaris | Phase 4 | Status: UNKNOWN